plasma cell differentiation

Programming B Cells to Deliver Novel Therapies for Patients How We’re Doing It Immusoft is the world leader in engineering B cells as biofactories for therapeutic protein delivery, a novel approach that we have pioneered. Our platform, called Immune System Programming (ISP™) entails collecting a type of the patient’s immune cells, called B cells. In response to immune stimulation, B cells can turn into biofactories (known as plasma cells), each of which manufactures and secretes thousands of antibodies per second. We harness this biofactory capability of the plasma cell by programming B cells to produce personalized protein therapeutics. Once we have programmed the B cells, we then expand and differentiate into plasma cells that will then produce large amounts of our therapeutic protein. In the clinic, we then infuse the programmed cells back into the patient, where they take up.

Read more

B cell engineeringcell therapyclinical developmentpreclinical research